source
- Osivax licenses GC Biopharma seasonal flu vaccine to develop combined OVX836-GC FLU shotOsivax has secured a non-exclusive license from GC Biopharma for its seasonal influenza vaccine, GC FLU, to pair with Osivax’s mid-phase candidate OVX836. OVX836 targets the conserved nucleoprotei…
- Spyre Therapeutics cuts rheumatoid arthritis program after weak Phase 2 TL1A antibody resultsSpyre Therapeutics reported that its Phase 2 study of the anti‑TL1A antibody SPY072 in rheumatoid arthritis did not meet the efficacy expectations set earlier this year. The company said the data f…